Spark’s de­liv­ery vec­tor trig­gers an­oth­er trou­bling im­mune re­ac­tion, but R&D team main­tains he­mo­phil­ia B ef­fi­ca­cy

One month af­ter Spark Ther­a­peu­tics $ONCE spooked its in­vestors with the news of one im­mune re­ac­tion to its gene ther­a­py in a small he­mo­phil­ia B study, its in­ves­ti­ga­tors turned up at ASH to add one more case to con­cern its back­ers. But the biotech wasn’t un­pre­pared, com­ing back with ev­i­dence that they were still able to con­trol the im­mune re­ac­tion to SPK-9001 while all but one of 9 pa­tients clear­ly re­mained free of bleeds.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.